Clozapine-induced myocarditis: Role of catecholamines in a murine model

European Journal of Pharmacology

Volumn 592, Issue 1-3, 2008, Pages 123-127

  Wang, Ju Feng ^a   Min, Jiang Yong ^a   Hampton, Thomas G ^a   Amende, Ivo ^b   Yan, Xinhua ^c   Malek, Sohail ^a   Abelmann, Walter H ^a   Green, Alan I ^d   Zeind, John ^a   Morgan, James P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c TUFTS UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Atypical antipsychotic; Balb C mice; Cardiotoxicity; Epinephrine; Norepinephrine; TNF alpha

Indexed keywords

ADRENALIN; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CLOZAPINE; CYTOKINE; NORADRENALIN; PROPRANOLOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CARDIOTOXICITY; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; CATECHOLAMINES; CLOZAPINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; PROPRANOLOL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49749083052     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.088     Document Type: Article

References (37)

1. Ackenheil M., Beckmann H., Greil W., Hoffman G., Markianos E., and Raese J. Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man. Adv. Biochem. Psychopharmacol. 9 (1974) 647-657
2. Anton A.H., and Sayre D.F. A study of the factors affecting the aluminum oxide trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther. 138 (1962) 360-375
3. Brown A.S., Gewirtz G., Harkavy-Friedman J., Cooper T., Brebion G., Amador X.F., Malaspina D., and Gorman J.M. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 17 (1997) 317-325
4. Cho T., Tanimura A., and Saito Y. Catecholamine-induced cardiopathy accompanied with pheochromocytoma. Acta. Pathol. Jpn. 37 (1987) 123-132
5. Coulter D.M., Bate A., Meyboom R.H., Lindquist M., and Edwards I.R. Antipsychotic drugs and heart muscle disorder international pharmacovigilance: data mining study. BMJ 1322 (2001) 1207-1209
6. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., and Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 20 (1999) 29-34
7. Fleischhaker C., Schultz E., and Remschmidt H. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia. J. Psychiatr. Res. 32 (1998) 325-333
8. Gimenez-Roldan S., Mateo D., Navarro E., and Gines M.M. Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Relat. Disord. 7 (2001) 121-127
9. Green A.I., Alam M.Y., Sobieraj J.T., Pappalardo K.M., Waternaux C., Salzmann C., Schatzberg A.F., and Schildkraut J.J. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res. 46 (1993) 139-149
10. Green A.I., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., Chang H., Zarate C., Posener J., Lee H., Dawson R., Richards C., and Cole J.O. Clozapine in the treatment of refractory psychotic mania. Am. J. Psychiatry 157 (2000) 982-986
11. Gross G., and Schühmann H.J. Enhancement of noradrenaline release from rat cerebral cortex by neuroleptic drugs. Naunyn Schmiedebergs Arch. Pharmacol. 315 (1980) 103-109
12. Gross G., and Schühmann H.J. Effect of long term treatment with atypical neuroleptic drugs on beta adrenoceptor binding in rat cerebral cortex and myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 321 (1982) 271-275
13. Haack M.J., Bak M.L., Beurskens R., Maes M., Stolk L.M., and Delespaul P.A. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur. Neuropsychopharmacol. 13 (2003) 381-385
14. Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., and McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 30 (2007) 47-57
15. Hagg S., Spigset O., Bate A., and Soderstrom T.G. Myocarditis related to clozapine treatment. J. Clin. Psychopharmacol. 21 (2001) 382-388
16. Hinze-Selch D., Deuschle M., Weber B., Heuser I., and Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl). 149 (2000) 163-169
17. Jensen V.E., and Gotzsche O. Allergic myocarditis in clozapine treatment. Ugeskr. Laeger. 156 (1994) 4151-4152
18. Kaur G., and Kulkarni S.K. Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 277-285
19. Kelly D.L., Conley R.R., Richardson C.M., Tamminga C.A., and Carpenter Jr. W.T. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann. Clin. Psychiatry. 15 (2003) 181-186
20. Killian J.G., Kerr K., Lawrence C., and Celermajer D.S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354 (1999) 1841-1845
21. Klieser E., Lehmann E., Kinzler E., Wurthmann C., and Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 15 1 Suppl 1 (1995) 45-51
22. Krentz A.J., Mikhail S., Cantrell P., and Hill G.M. Pseudophaeochromocytoma syndrome associated with clozapine. BMJ. 322 (2001) 1213
23. LaGrenade L., Graham D., and Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N. Engl. J. Med. 345 (2001) 224-225
24. Li J.K., Yeung V.T., Leung C.M., Chow C.C., Ko G.T., So W.Y., and Cockram C.S. Clozapine: a mimicry of phaeochromocytoma. Aust. N Z. J. Psychiatry. 31 (1997) 889-891
25. Manzaneque J.M., Brain P.F., and Navarro J.F. Effect of low doses of clozapine on behaviour of isolated and group-housed male mice in elevated plus-maze test. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 349-355
26. Matsumori A., Wang H., Abelmann W.H., and Crumpacker C.S. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation. 71 (1985) 834-839
27. Merrill D.B., Dec G.W., and Goff D.C. Adverse cardiac effects associated with clozapine J. Clin. Psychopharmacol. 25 (2005) 32-41
28. Merrill D.B., Ahmari S.E., Bradford J.M., and Lieberman J.A. Myocarditis during clozapine treatment. Am. J. Psychiatry 163 (2006) 204-208
29. Nishio R., Matsumori A., Shioi T., Ishida H., and Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation. 100 (1999) 1102-1108
30. Pastor C.A., and Mehta M. Masked clozapine-induced cardiomyopathy. J. Am. Board Fam. Med. 21 (2008) 70-74
31. Pollmächer T., Hinze-Selch D., and Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16 (1996) 403-409
32. Pollmächer T., Schuld A., Kraus T., Haack M., and Hinze-Selch D. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr. Neurol. Psychiatr. 69 Suppl 2 (2001) 65-74
33. Qiao H., Noda Y., Kamei H., Nagal T., Furukawa H., Miura H., and Kayukawa Y. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencydlidine treatment. Neuroreport 12 (2001) 11-15
34. Scratchley G.A., Masoud A.N., Stohs S.J., and Wingard D.W. High performance liquid chromatographic separation and determination of catecholamines and related compounds. J. Chromatography. 169 (1997) 313-319
35. Van Vliet P.D., Burchell H.B., and Titus J.L. Focal myocarditis associated with pheocromocytoma. N. Engl. J. Med. 274 (1966) 1102-1108
36. Wang J.F., Meissner A., Malek S., Chen Y., Ke Q., Zhang J., Chu V., Hampton T.G., Crumpacker C.S., Abelmann W.H., Amende I., and Morgan J.P. Propranolol ameliorates and adrenaline exacerbates progression of acute and chronic viral myocarditis. Am. J. Physiol. 289 (2005) H1577-1583
37. Wehmeier P.M., Heiser P., and Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J. Clin. Pharm. Ther. 30 (2005) 91-96